Back issues No.2 - 1996 / Original Study  

Full Text PDF


A Double-blind, Randomized, Parallel and Controlled Study to Evaluate Fluticasone Propionate 0.05% Cream Applied Twice Daily in the Treatment of Psoriasis
Heng-Leong Chan, Chung-Li Huang
Dermatol Sinica 14: 65-70, 1996

The safety and efficacy of fluticasone propionate (CutivateTM) cream 0.05% was studied in 50 psoriatic patients. The patients were enrolled in a double blind, randomized, parallel and controlled trial. Patients who met the inclusion criteria were given fluticasone propionate 0.05% or betamethasone valerate 0.1%. Assessment criteria included the clinical signs and symptoms of the target lesion (pruritus, erythema, plaques and scaling), physician's gross assessment of response to therapy, subjective assessment, and adverse events. 120gm of fluticasone propionate or betamethasone valerate were administered over a 4 week period using a bid topical application. Adverse effects were rare. Only one case in the trial group experienced burning sensation, whereas none in the control group did. No differences in the signs and symptoms of the target lesion were noted on day 29. The lesions were improved by a mean score of 3.50 in the control group and 3.36 in the trial group. For patient subjective assessment, on day 29, 16 (80%) of 20 patients receiving the control drug reported fair, good or excellent responses, while 17 (77.3%) of 22 who received the trial drug did so. The responses assessed by physicians was approximately similar between the trial and control groups, 17 (85%) of 20 control patients had fair, good or excellent response, while 19 (86.4%) of 22 who received the trial drug did. This study demonstrated that the administration of fluticasone propionate did is safe and resulted in improvement in symptoms of psoriatic patients.

You are visitors    
Copyright © 2008 THE Taiwanese Dermatological Association. All Rights Reserved. Email: Tel:886-2-2518-5126~7 Fax:886-2-2518-5128